CRTX News and Press, Cortexyme Inc. From 08/09/21

GAIN Trial top-line data for disease modification in Alzheimer’s expected by mid-November 2021 Phase 2 REPAIR sub-study results evaluating periodontal disease expected by mid-November 2021 Current cash position sufficient to fund operations through 2023 ...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris Lowe, the company’s chief operating officer a...

New GAIN Trial baseline data demonstrates majority of patients have elevated Von Willebrand factor and alpha-2-macroglobulin Cortexyme to host AAIC symposium titled “Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Diseas...

You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Tech heavyweights will be in the spotlight next week with Apple (NASDAQ:AAPL), Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ...

Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...

Cortexyme (CRTX) announces the selection of a lead 3CLpro inhibitor COR803 for the treatment of COVID-19 infections.The company argued that COR803 has beneficial properties over other COVID-19 therapeutics and 3CLpro inhibitors in development.Shares down marginally premarket. For further de...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for t...

Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases , announced that it will present two poster presentations cove...

Leading drug candidate penetrates and disrupts bacterial biofilms, a key feature for efficacy in treating P. gingivalis driven disease Atuzaginstat reverses alveolar bone loss in mice after oral P. gingivalis infection at doses relevant for therapeutic efficacy in periodontal ...